RAMAT GAN, Israel--(BUSINESS WIRE)--Zetiq Technologies Ltd. (“Zetiq”), a subsidiary of Bio-Light Ltd. (TASE: BOLT), reports the successful completion of another clinical trial to validate the effectiveness of the company’s technology for early identification and diagnosis of cervical cancer, in conventional cytological smears.
